Peptide Nucleic Acids (PNAs) in Antimicrobial Therapy: A Next Generation Strategy
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27031565 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Antonia D'Aniello und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Crystallography, National Research Council of Italy, URT Caserta, Via Vivaldi 43, 81100 Caserta, Italy. Hauptthemen laut MEDLINE: Peptide Nucleic Acids, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: "National Center for Gene Therapy and Drugs based on RNA Technology", Progetti@CNR (comma 6.5 "I Avviso-2020" dei Progetti di Ricerca@CNR del 27 November 2020), MIUR PNRR “National Center for Gene Therapy and Drugs based on RNA Technology”.
Abstract (Originalsprache)
The global rise in antimicrobial resistance (AMR) demands innovative strategies beyond traditional antibiotics. Peptide Nucleic Acids (PNAs), synthetic DNA analogues with peptide-like backbones, act as thermically, chemically, and enzymatically stable sequence-specific agents capable of silencing essential bacterial genes. Through antisense mechanisms, PNAs bind bacterial mRNA or rRNA, blocking translation or ribosome assembly and thereby inducing species-specific growth inhibition. Their programmable design enables precise targeting of multidrug-resistant pathogens while sparing commensal microbiota. Recent advances, including γ-modified backbones, cationic substitutions, and delivery platforms such as cell-penetrating peptides (CPPs), dendron conjugates, and nanoparticles, have improved solubility, stability, and cellular uptake. Studies show promising in vitro and, albeit less frequently, in vivo efficacy against both Gram-positive and Gram-negative bacteria, often with synergistic activity when combined with conventional antibiotics. Although challenges remain in delivery and large-scale production, PNAs represent a promising class of antimicrobials to combat AMR through targeted gene inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Crystallography, National Research Council of Italy, URT Caserta, Via Vivaldi 43, 81100 Caserta, Italy.
- Institute of Crystallography, National Research Council of Italy, Strada Provinciale 35d, 9, Montelibretti, 00010 Rome, Italy.
ORCID-Profile: Antonia D'Aniello, Annalisa Masi, Concetta Avitabile, Michele Saviano, Maria Moccia
Förderung
- "National Center for Gene Therapy and Drugs based on RNA Technology"
- Progetti@CNR (comma 6.5 "I Avviso-2020" dei Progetti di Ricerca@CNR del 27 November 2020)
- MIUR PNRR “National Center for Gene Therapy and Drugs based on RNA Technology”
Zitieren
APA
D'Aniello, A., Masi, A., Avitabile, C., Del Monaco, G., Saviano, M., & Moccia, M. (2026). Peptide Nucleic Acids (PNAs) in Antimicrobial Therapy: A Next Generation Strategy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27031565
Vancouver
D'Aniello A, Masi A, Avitabile C, Del Monaco G, Saviano M, Moccia M. Peptide Nucleic Acids (PNAs) in Antimicrobial Therapy: A Next Generation Strategy. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27031565
BibTeX
@article{DAniello2026,
author = {D'Aniello, Antonia and Masi, Annalisa and Avitabile, Concetta and Del Monaco, Giovanni and Saviano, Michele and Moccia, Maria},
title = {Peptide Nucleic Acids (PNAs) in Antimicrobial Therapy: A Next Generation Strategy},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27031565}
}
EUVIMED